The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.
|Articles|July 20, 2012
Meet the Experts - Cardiology Now
Dr Payal Kohli, a recent graduate of the Harvard Medical School, is currently a fellow in cardiovascular medicine at the University of California San Francisco.
Advertisement
Dr Payal Kohli, a recent graduate of the Harvard Medical School, is currently a fellow in cardiovascular medicine at the University of California San Francisco.
Advertisement
Related to this article
Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.
Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.
Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Greater Mediterranean diet adherence was associated with lower odds of adult acne, particularly among women, in a UK Biobank study of dietary patterns.
Abbott's investigational device achieved 96.3% complete left atrial appendage closure by echocardiography, with a 1.8% ischemic stroke rate at 1 year.
October FDA news included updates on long-acting olanzapine, multi-cancer blood testing, stroke rehabilitation, and heart failure monitoring.
Advertisement
Advertisement
Trending on Patient Care Online
1
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
2
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
3
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
4
New Study Shows Menopause Undercoded in Primary Care, With Gaps by Race and Insurance
5